abstract |
The present invention describes prolyl hydroxylase inhibitors that can stabilize hypoxia-inducible factor-1 alpha (HIF-la), as well as hypoxia-inducible factor-2 alpha (HIF-2); Pharmaceutical compositions comprising one or more of the compounds described are also described herein; methods for stimulating the cellular immune response in a mammal such as an increase in phagocytosis are also described, for example, prolonging the life of phagocytes, among others, keratinocytes, neutrophils; As such, the compounds described provide methods for treating diseases that are related to the body's immune response. |